---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028771"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:47:35.821810+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics Q3 2022 net loss $12.0M; $137.9M cash; OV329 Phase 1 to start Q4

## Summary
- Net loss of $12.0M ($0.17 per share) vs $11.4M loss in Q3 2021; R&D expense $5.2M.
- Cash, cash equivalents and marketable securities totaled $137.9M as of Sept 30, 2022.
- FDA cleared IND for OV329; Phase 1 trial in healthy volunteers planned for Q4 2022.
- Executed additional $3.5M investment in Gensaic convertible preferred stock for gene delivery platform.
- Takeda continues pivotal Phase 3 trials for soticlestat; Ovid eligible for up to $660M milestones plus royalties.

## SEC filing metadata
- accession: 0001628280-22-028771
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828022028771/0001628280-22-028771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828022028771/ovid-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028771
- JSON: https://secwatch.observer/filing/0001628280-22-028771.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028771.txt

## Key facts
- Earnings Releases
  Ovid Therapeutics Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022 , Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Third Quarter 2022 Financial Results and Corporate Highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000162828022028771/0001628280-22-028771-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.